VXRT vs. CRDL, CRDF, XFOR, VCXB, VIGL, CLLS, SCLX, OMGA, MOLN, and LIFE
Should you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Cardiol Therapeutics (CRDL), Cardiff Oncology (CRDF), X4 Pharmaceuticals (XFOR), 10X Capital Venture Acquisition Corp. III (VCXB), Vigil Neuroscience (VIGL), Cellectis (CLLS), Scilex (SCLX), Omega Therapeutics (OMGA), Molecular Partners (MOLN), and aTyr Pharma (LIFE). These companies are all part of the "biological products, except diagnostic" industry.
Vaxart (NASDAQ:VXRT) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
Vaxart currently has a consensus target price of $3.00, indicating a potential upside of 212.89%. Cardiol Therapeutics has a consensus target price of $6.00, indicating a potential upside of 176.50%. Given Vaxart's higher possible upside, equities analysts clearly believe Vaxart is more favorable than Cardiol Therapeutics.
Cardiol Therapeutics has lower revenue, but higher earnings than Vaxart. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.
18.1% of Vaxart shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 3.0% of Vaxart shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Cardiol Therapeutics has a net margin of 0.00% compared to Vaxart's net margin of -920.00%. Cardiol Therapeutics' return on equity of -98.90% beat Vaxart's return on equity.
In the previous week, Cardiol Therapeutics had 1 more articles in the media than Vaxart. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 6 mentions for Vaxart. Vaxart's average media sentiment score of 0.75 beat Cardiol Therapeutics' score of 0.06 indicating that Vaxart is being referred to more favorably in the media.
Vaxart has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Vaxart received 294 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 65.47% of users gave Vaxart an outperform vote while only 51.72% of users gave Cardiol Therapeutics an outperform vote.
Summary
Cardiol Therapeutics beats Vaxart on 10 of the 17 factors compared between the two stocks.
Get Vaxart News Delivered to You Automatically
Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
